The European Commission approved a dosing schedule for Bristol-Myers Squibb’s Opdivo (nivolumab) as adjuvant treatment in adult melanoma patients with lymph node involvement or metastatic disease who have undergone complete resection.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
